June 9, 2026

Meta-analysis: Cognitive Behavioral Therapy for Adult ADHD

A recent meta-analysis examined how well cognitive behavioral therapy (CBT) improves not just symptoms, but everyday functioning and quality of life in adults with ADHD. 

The Background:

ADHD in adults affects far more than attention or impulsivity. It often disrupts key areas of life: 

  • Education: Adults with ADHD tend to have lower GPAs, use fewer effective study strategies, achieve less academically, and are more likely to drop out.  
  • Work: They are more likely to experience job instability, including underperformance, unemployment, being fired, or frequent job changes.  
  • Social life: They often report smaller social networks, fewer close relationships, greater loneliness, and difficulty maintaining friendships or intimacy. Importantly, stronger social networks can help buffer (reduce) the impact of ADHD symptoms on daily life.  
  • Quality of life: Overall well-being is typically lower, affecting not only individuals but also their families and close relationships.

These broad impacts highlight a key issue: reducing symptoms does not automatically translate into better day-to-day functioning. 

CBT is a structured, skills-based therapy that helps people: 

  • Identify and challenge unhelpful thought patterns  
  • Reduce avoidance behaviors  
  • Build practical strategies for managing time, organization, and other executive functions (the mental skills used to plan, focus, and follow through)  

While both medication (especially stimulants) and CBT improve core ADHD symptoms, CBT is particularly aimed at improving real-world functioning. 

The Study:

The researchers analyzed studies involving adults diagnosed with ADHD (or showing clinically significant symptoms). They included: 

  • Randomized controlled trials (RCTs): studies comparing CBT to another treatment or to no treatment  
  • Within-subject studies: studies measuring change in the same individuals before and after CBT  

They focused specifically on outcomes beyond symptoms: 

  • Occupational functioning (work performance)  
  • Global functional impairment (overall daily functioning)  
  • Social relationships  
  • Academic functioning  
  • Quality of life  

The Results:

1.  Strongest Effects: Occupational functioning
CBT showed consistently strong improvements in work-related functioning compared to control groups, both immediately after treatment and at follow-up. This was the most robust finding across domains. 

2. Moderate Improvement: Global Functional Impairment
CBT led to moderate improvements in overall daily functioning, with some evidence that gains persist over time. In studies tracking individuals over time, improvements were even stronger at follow-up. 

3. Modest Gains: Social Relationships
CBT produced small to moderate improvements in social functioning. Benefits were present both after treatment and at follow-up, but were less pronounced than in work-related outcomes. 

4. Limited Effects: Academic Functioning
There were moderate short-term gains when CBT was compared to control groups, but these did not persist at follow-up. Within-subject studies showed only small improvements overall. 

5. Modest and Inconsistent Effects: Quality of Life
Improvements in quality of life were small when compared to control groups and often did not last. However, studies tracking individuals over time showed moderate improvements, suggesting some benefit that may not always show up clearly in between-group comparisons. 

Overall, the findings suggest: 

  • CBT does improve real-world functioning, not just symptoms  
  • The strongest and most consistent benefits are in occupational (work) functioning  
  • Gains in social life, academics, and overall quality of life are more modest and variable  
  • Improvements in functioning do not always track directly with symptom reduction  

One notable nuance: CBT did not always outperform other active treatments (like medication or other therapies). This suggests that while CBT is effective, its benefits may partly overlap with broader therapeutic or support effects rather than relying on a single, unique mechanism. 

The Take-Away: 

CBT is a valuable, evidence-based treatment for adults with ADHD, especially for improving work functioning and overall daily life management. However, its impact on relationships, academic outcomes, and quality of life is more limited and less consistent, pointing to the need for more targeted or combined approaches in those areas. 

 

Carlos López-Pinar, Benjamin Selaskowski, Marcel Schulze, Martin Oscarsson, Javier Fenollar-Cortés, Margaret H. Sibley, Alexandra Philipsen, and Tatja Hirvikoski, “Cognitive behavioral therapy effects on global functioning, domain-specific functioning, and quality of life in adult ADHD: A comprehensive meta-analysis,” Behaviour Research and Therapy 201 (2026) 105026, published online, https://doi.org/10.1016/j.brat.2026.105026

Related posts

Cognitive Behavioral Therapy for ADHD: What is it? Does it work?

Cognitive Behavioral Therapy for ADHD: What is it? Does it work?

Cognitive Behavioral Therapy (CBT) is a one-to-one therapy, for adolescents or adults, where a therapist teaches an ADHD patient how thoughts, feelings, and behaviors are all interrelated and how each of these elements affects the others.  CBT emphasizes cognition or thinking because a major goal of this therapy is to help patients identify thinking patterns that lead to problem behaviors.  For example, the therapist might discover that the patient frequently has negative automatic thoughts such as "I'm stupid" in challenging situations. We call the thought 'automatic' because it invades the patient's consciousness without any effort. Thinking "I'm stupid" can cause anxiety and depression, which leads to failure. Thus, stopping the automatic thought will modify this chain of events and, hopefully, improve the outcome from failure to success.

CBT also educates patients about their ADHD and how it affects them in important daily activities.


For example, most ADHD patients need help with activity schedules, socializing, organizing their workspace, and controlling their distractibility. By teaching specific cognitive and behavioral skills, the therapist helps the patient deal with their ADHD symptoms productively. For example, some ADHD patients are very impulsive when conversing with others. They don't wait their turn during conversations and may blurt out irrelevant ideas. This can be annoying to others, especially in the context of school or business relationships. The CBT therapist helps the patient identify these behaviors and creates strategies for avoiding them.

So, does CBT work for ADHD? The evidence base is small, but when CBT has been used for adult ADHD, it has produced positive results in well-designed studies.   These studies typically compare patients taking ADHD medications with those taking ADHD medications and receiving CBT.  

So for now, it is best to consider CBT as an adjunct rather than a replacement for medication. There are even fewer studies of CBT for adolescents with ADHD.  These initial studies also suggest that CBT will be useful for adolescents with ADHD who are also taking ADHD medications.  Some data suggest that CBT can be successfully applied in the classroom, but the evidence base is very small.

How can this information be used by doctors and patients for treatment planning?  Current treatment guidelines suggest starting with an ADHD medication.  After a suitable medication and dose are found, the patient and doctor should determine if any problems remain.  If so, CBT should be considered an adjunct to ADHD medications.

April 19, 2021

Mindfulness-Based Cognitive Therapy for Adults with ADHD

Mindfulness-Based Cognitive Therapy for Adults with ADHD

A Dutch study compared the efficacy of mindfulness-based cognitive therapy (MBCT) combined with treatment as usual (TAU), with TAU-only as the control group. MBCT consisted of an eight-week group therapy consisting of meditation exercises (body scan, sitting meditation, mindful movement), psychoeducation about ADHD, and group exercises. TAU consisted of usual treatment in the Netherlands, including medications and other psychological treatments. Sixty individuals were randomly assigned to each group. MBCT was taught in subgroups of 8 to 12 individuals. Patients assigned to TAU were not brought together in small groups. Baseline demographic and clinical characteristics were closely matched for both groups.

Outcomes were evaluated at the start, immediately following treatment, and again after 3 and 6 months using well-validated rating scales. Following treatment, the MBCT + TAU group outperformed the TAU group by an average of 3.4points on the Conner's Adult Rating Scale, corresponding to a standardized mean difference of .41. Thirty-one percent of the MBCT + TAU group made significant gains, versus 5% of the TAU group. 27% of MBCT +TAU patients scored a symptom reduction of at least 30 percent, as opposed to only 4% of TAU patients. Three and six-month follow-up effects were stable, with an effect size of .43.

The authors concluded, "that MBCT has significant benefits to adults with ADHD up to 6 months after post-treatment, about both ADHD symptoms and positive outcomes." Yet in their section on limitations, they overlook a potentially important one. There was no active placebo control. Those who were undergoing TAU-only were aware that they were not doing anything different from what they had been doing before the study. Hence, no substantial placebo response would be expected from this group during the intervention period (post-treatment they were offered an opportunity to undergo MBCT). Moreover, MBCT + TAU participants were gathered into small groups, whereas TAU participants were not. We, therefore, have no way of knowing what effect group interaction had on the outcomes because it was not controlled for. So, although these results are intriguing and suggest that further research is worthwhile, the work is not sufficiently rigorous to definitively conclude that MBCT should be prescribed for adults with ADHD.

June 8, 2021

Is Cognitive Behavior Therapy Effective for Treating Adult ADHD?

Is Cognitive Behavior Therapy Effective for Treating Adult ADHD?

The term "cognitive behavior therapy (CBT)" refers to a type of talk therapy that seeks to change the way patients think about themselves, their disorder, and the world around them in a manner that will help them overcome symptoms and achieve life goals.

Because CBT is typically administered by a psychologist or other mental health professionals, CBT services are not available in primary care. Nonetheless, it is useful for primary care practitioners to know about CBT so that they can refer appropriately as needed. So, what can we say about the efficacy of CBT for treating adults with ADHD?

Based on a meta-analysis by Young and colleagues, we know for certain that the number of published trials of CBT for adult ADHD is small; only nine trials are available. Five of these compared CBT with waiting list controls; three compared CBT with appropriate placebo control groups. In all of these studies, patients in the CBT and control groups were also being treated with ADHD medications.

Thus, they speak to the efficacy of CBT when given as an adjunctive treatment. The meta-analysis examined the waiting list controlled studies and the placebo-controlled studies separately. For both types of study, the effect of CBT in reducing ADHD symptoms was statistically significant, with a standardized mean effect size of 0.4.

This effect size, albeit modest, is large enough to conclude that CBT will be useful for some patients being treated with ADHD medications. Given these results, a reasonable guideline would be to refer adults with ADHD to a CBT therapist if they are being maintained on an ADHD medication, but that medication is not leading to a complete remission of their symptoms and impairments. So listen to your patients. If, while on an appropriately titrated medication regime, they still complain about unresolved symptoms or impairments, you need to take action.  In some cases, changing their dose or shifting to another medication will be useful. If such approaches fail or are not feasible, you should consider referral to a CBT therapist.

April 17, 2021

A New ADHD Medication That Works Differently in the Brain

The FDA has approved a new once-daily pill called centanafadine (trade name SIMTRIYO®). Approved for adults and kids aged 6 and older (weighing at least 44 lbs / 20 kg), centanafadine is a new category of ADHD treatment that aims to give fast results with fewer of the downsides of traditional stimulants.

What Makes This Drug Different?

To understand why centanafadine is unique among medications for ADHD, it helps to look at how ADHD brain chemistry works:

  1. Norepinephrine: Powers focus, alertness, and attention span.
  1. Dopamine: Drives motivation, reward system, and decision-making.
  1. Serotonin: Regulates mood, anxiety levels, and emotional stability.

Stimulants like Ritalin and Adderall work mainly in the dopamine system.  Nonstimulants like atomoxetine, viloxazine, clonidine and guanfacine work mainly on the norepinephrine system.  Centanafadine is the first drug in a new class called NDSRIs (Norepinephrine, Dopamine, and Serotonin Reuptake Inhibitors). We can describe its effects as follows:

  • Heavy boost to Norepinephrine: Delivers the strong focus and attention boost you need.
  • Moderate, smooth increase to Dopamine: Helps with motivation and brain executive function without triggering massive dopamine spikes that lead to addiction or heavy crashes.
  • Moderate boost to Serotonin: Helps smooth out mood swings and keeps anxiety under control.

What Did Clinical Trials Show?

The FDA approved centanafadine based on studies involving thousands of adults, teens, and children. Here are the key findings:

Centanafadine showed some improvement in ADHD symptoms within the very first week of taking it although a full effect takes about six weeks.

In adult trials, taking 200 mg or 400 mg daily led to significant improvements in real-world skills:

  • Time management and prioritizing tasks
  • Starting projects without procrastinating
  • Planning complex tasks and staying organized
  • Short-term working memory

In trials with children (ages 6–12) and teens (ages 13–17), centanafadine significantly reduced core ADHD symptoms like hyperactivity, impulsivity, and lack of focus compared to a placebo.

About 30% to 40% of adults with ADHD also suffer from anxiety. Traditional stimulants can make anxiety worse. In a trial specifically designed for adults dealing with both ADHD and anxiety, centanafadine effectively treated ADHD symptoms without firing up their anxiety, which might be due to its serotonin boost.

Does Centanafadine have Side Effects?

While Centanafadine was well-tolerated by most people in studies, like any prescription medication, it comes with important safety guidelines.

Prescribing Warnings:

  • Suicidal Thoughts in Children: In trials for kids aged 6 to 12, centanafadine was linked to a higher risk of suicidal thoughts and behaviors compared to a sugar pill.  Although rare, parents and doctors should look for changes in mood or behavior, especially when starting or changing doses.
  • Stimulant Classification: Because it acts on central nervous system pathways, especially dopamine, centanafadine is classified as a CNS stimulant so might lead to addiction. While it has a much lower abuse risk than stimulants like Ritalin or Adderall, doctors should still evaluate patients for any history of substance abuse before prescribing.

Common Side Effects:

  • Kids & Teens: Decreased appetite, stomach ache, nausea, rash, and headache.
  • Adults: Dry mouth, difficulty sleeping (insomnia), decreased appetite, nausea, and headaches.

Other Warnings:

  • Heart & Blood Pressure: It can cause small increases in heart rate and blood pressure, so doctors will check these regularly.
  • Drug Interactions: It cannot be taken with certain antidepressants (MAOIs) due to dangerous blood pressure risks.

The Bottom Line

Overall, centanafadine is a new step forward in how we treat ADHD. Because it acts differently in the brain than traditional treatments, patients who struggle with stimulant-related anxiety or side effects may find it useful to explore with their doctor.

Nitrogen Dioxide Linked to Higher ADHD Risk: Insights from a Massive South Korean Study

A landmark nationwide study from South Korea has uncovered a significant link between prenatal exposure to air pollution — specifically nitrogen dioxide (NO2) — and an increased risk of ADHD in children. 

While researchers have long suspected that air pollutants interfere with fetal brain development through inflammation and oxidative stress, this study is one of the largest and most comprehensive of its kind, following nearly 1.5 million births for up to 13 years. 

Why South Korea? 

South Korea provided a unique countrywide “laboratory” for this research due to two key infrastructure strengths: 

  • Universal Health Data: A national insurance database that tracks the health outcomes of the entire population. 
  • Granular Air Monitoring: A network of 642 monitoring stations that allowed researchers to precisely estimate what pollutants mothers were breathing based on their postal codes. 

Key Findings: The “Smoking Gun” of NO2 

While the study looked at several pollutants, nitrogen dioxide — a byproduct of fossil fuel combustion in cars and power plants — emerged as the primary concern. 

Pollutant 

Association with ADHD Risk 

Nitrogen Dioxide (NO2) 

Strongest Link: Every 1-ppb (part-per-billion) increase in exposure linked to a 22% rise in risk. 

Sulfur Dioxide (SO2) 

Minimal Link: Only a slight 4% increase per ppb. 

Ozone (O3) carbon monoxide (CO), & particulates 

No significant association was found. 

The scale of the NO2 risk is particularly striking. Over the typical range of exposure levels found in the study (an interquartile range of 13 ppb), the data suggest a threefold increase in ADHD risk for children in the highest-exposure groups compared to the lowest. 

Accounting for Other Factors 

To ensure the results weren’t skewed by other variables, the researchers controlled for a wide range of confounders including: 

  • Socioeconomic and employment status. 
  • Maternal age and baseline health. 
  • The child’s sex. 
  • The presence of 14 different medical conditions around childbirth. 

The authors emphasized the strong association between maternal nitrogen dioxide exposure and ADHD, while also noting the small but significant association with sulfur dioxide.  

The Take-Away: A New Frontier for Public Health 

Historically, air quality laws have been designed to protect our lungs and hearts. However, this study adds to a growing body of evidence suggesting that the brain is likewise vulnerable. 

In a commentary on the findings, expert George Ayoub argued that “neurodevelopment should be explicitly considered” when governments perform cost-benefit analyses on air quality regulation.  My view is a bit different.  The association is intriguing but the study does not establish cause and effect.  Many statistically significant environmental risk associations for neurodevelopmental disorders have disappeared after controlling for maternal risk for ADHD.  I hope this research team will do those analyses if feasible.

New Meta-analysis Finds Structured Executive Function Training Largely Ineffective

Executive functions (EFs) are the cognitive control systems that allow people to pursue goals, make decisions, and adapt to changing circumstances. Researchers generally break them into three overlapping capacities: working memory (holding and manipulating information in mind), inhibitory control (suppressing impulses and filtering out distractions), and cognitive flexibility (switching between tasks or mental frameworks). Strong EFs in childhood predict academic achievement, social competence, and long-term mental health; weaknesses in these areas that go unaddressed can persist into adulthood, undermining school performance, career prospects, and well-being. 

The Background:

Interest in training these skills has grown rapidly, but most research has been conducted in Western settings. China presents a distinctive context. Collectivist values make group-based programs culturally natural, and parental investment in academic outcomes is high. Both of these factors should, in theory, work in an intervention’s favor. At the same time, tightly scheduled school days (sessions typically capped at 30 minutes or less) constrain what is actually deliverable. A growing number of randomized controlled trials (RCTs) have tested EF interventions with Chinese children, but until now, no one has pulled that evidence together systematically. 

The Study:

A new network meta-analysis did exactly that. The researchers screened RCTs involving Chinese children aged 3–12, including both typically developing children and those showing subclinical signs of ADHD or autism spectrum disorder (ASD), for instance, siblings of children with an ASD diagnosis. Children who already carried a formal neurodevelopmental diagnosis were excluded. Fifty-two trials covering nearly 3,000 children met the inclusion criteria. Interventions fell into four categories: 

  • Computerized adaptive n-back training with metacognitive coaching (strategy instruction and self-monitoring): 14 trials, 486 children 
  • Stop-signal and rule-switching tasks targeting inhibitory control and cognitive flexibility, delivered face-to-face: 18 trials, 632 children 
  • Hybrid physical-cognitive training moderate-to-vigorous aerobic exercise combined with concurrent cognitive demands (e.g., brisk walking while counting backward) in 20–30-minute sessions: 10 trials, 298 children 
  • Computerized cognitive flexibility training (set-shifting, dual-task coordination), self-paced with progressive difficulty: 10 trials, 312 children 

The headline finding is that three of the four intervention types produced statistically significant improvements across all three EF domains. The exception was the hybrid physical-cognitive program, which did not reach significance for inhibitory control. Positive results across the board might sound encouraging until you look at the actual effect sizes. 

The Results:

The actual effects were negligible. Every significant result fell well below what methodologists define as a “small” effect (a standardized mean difference, or SMD, of 0.2). The largest effect size in the entire analysis was an SMD of 0.097  (less than half that threshold). The authors summarize the interventions’ effects as “modest,” but that is generous phrasing for numbers that, in practical terms, amount to very little. The analysis also showed signs of publication bias, meaning that studies with null or negative results may not have been published, potentially inflating even these modest figures. 

The Take-Away: 

It is important to note that these results don’t necessarily mean that this is the last word on EF training. The results apply specifically to Chinese children working within the time constraints of Chinese school schedules, and they exclude children with diagnosed ADHD, a population for whom cognitive interventions sometimes show larger effects. Generalizing beyond those boundaries is unwarranted. 

What the findings do suggest is that structured EF programs, as currently implemented in Chinese educational settings, are not delivering meaningful real-world benefits. Statistical significance, it is worth remembering, is not the same as practical significance, and the gap between the two is sharp here. 

July 17, 2026